WKP|Q40644652

Search

Select Field:

Select Index:

Search Terms:

Leader		00000nz a2200037n 45 0
001		WKP\|Q40644652 (VIAF cluster) (Authority/Source Record)
003		WKP
005		20241221010835.0
008		241221nneanz\|\|abbn n and d
035		‎‡a (WKP)Q40644652‏
024		‎‡a 0000-0002-8404-0581‏ ‎‡2 orcid‏
024		‎‡a 55870592600‏ ‎‡2 scopus‏
035		‎‡a (OCoLC)Q40644652‏
100	0	‎‡a Jong Bong Lee‏ ‎‡9 sl‏
400	0	‎‡a Jong Bong Lee‏ ‎‡c researcher‏ ‎‡9 en‏
400	0	‎‡a Jong Bong Lee‏ ‎‡c wetenschapper‏ ‎‡9 nl‏
400	0	‎‡a Jong Bong Lee‏ ‎‡c investigador/a‏ ‎‡9 es‏
400	0	‎‡a Jong Bong Lee‏ ‎‡c investigador‏ ‎‡9 ast‏
670		‎‡a Author's A novel in vitro permeability assay using three-dimensional cell culture system.‏
670		‎‡a Author's A novel nucleoside rescue metabolic pathway may be responsible for therapeutic effect of orally administered cordycepin‏
670		‎‡a Author's Application of Size and Maturation Functions to Population Pharmacokinetic Modeling of Pediatric Patients‏
670		‎‡a Author's Assessment of bisphenol A exposure in Korean pregnant women by physiologically based pharmacokinetic modeling.‏
670		‎‡a Author's Cardiac glycoside cerberin exerts anticancer activity through PI3K/AKT/mTOR signal transduction inhibition‏
670		‎‡a Author's Determination of zearalenone by liquid chromatography/tandem mass spectrometry and application to a pharmacokinetic study.‏
670		‎‡a Author's Development and validation of a cost-effective and sensitive bioanalytical HPLC-UV method for determination of lopinavir in rat and human plasma‏
670		‎‡a Author's Development of Cordycepin Formulations for Preclinical and Clinical Studies‏
670		‎‡a Author's Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines‏
670		‎‡a Author's Disposition, oral bioavailability, and tissue distribution of zearalenone in rats at various dose levels.‏
670		‎‡a Author's Exposure assessment of epidermal growth factor to various tissues in mice after intravenous and subcutaneous administration‏
670		‎‡a Author's Hyperlipidaemia alone and in combination with acidosis can increase the incidence and severity of statin-induced myotoxicity‏
670		‎‡a Author's In vitro anticancer properties and biological evaluation of novel natural alkaloid jerantinine B.‏
670		‎‡a Author's Intradermal and transdermal drug delivery using microneedles - Fabrication, performance evaluation and application to lymphatic delivery‏
670		‎‡a Author's Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system‏
670		‎‡a Author's Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation.‏
670		‎‡a Author's Physiologically Relevant In Vitro-In Vivo Correlation (IVIVC) Approach for Sildenafil with Site-Dependent Dissolution‏
670		‎‡a Author's Prevention of paclitaxel-induced neuropathy by formulation approach‏
670		‎‡a Author's Quantitative analysis of lab-to-lab variability in Caco-2 permeability assays.‏
670		‎‡a Author's Quantitative Prediction of Oral Bioavailability of a Lipophilic Antineoplastic Drug Bexarotene Administered in Lipidic Formulation Using a Combined In Vitro Lipolysis/Microsomal Metabolism Approach‏
670		‎‡a Author's Self-Assembling Benzothiazole-Based Gelators: A Mechanistic Understanding of in Vitro Bioactivation and Gelation.‏
670		‎‡a Author's Simple and sensitive HPLC-UV method for determination of bexarotene in rat plasma.‏
670		‎‡a Author's Simultaneous determination of phenoxyethanol and its major metabolite, phenoxyacetic acid, in rat biological matrices by LC-MS/MS with polarity switching: Application to ADME studies‏
670		‎‡a Author's Simultaneous quantification of ondansetron and tariquidar in rat and human plasma using a high performance liquid chromatography-ultraviolet method‏
670		‎‡a Author's The role of acid-base imbalance in statin-induced myotoxicity‏
909		‎‡a (orcid) 0000000284040581‏ ‎‡9 1‏
909		‎‡a (scopus) 55870592600‏ ‎‡9 1‏
919		‎‡a applicationofsizeandmaturationfunctionstopopulationpharmacokineticmodelingofpediatricpatients‏ ‎‡A Application of Size and Maturation Functions to Population Pharmacokinetic Modeling of Pediatric Patients‏ ‎‡9 1‏
919		‎‡a novelnucleosiderescuemetabolicpathwaymayberesponsiblefortherapeuticeffectoforallyadministeredcordycepin‏ ‎‡A A novel nucleoside rescue metabolic pathway may be responsible for therapeutic effect of orally administered cordycepin‏ ‎‡9 1‏
919		‎‡a novelinvitropermeabilityassayusing3dimensionalcellculturesystem‏ ‎‡A A novel in vitro permeability assay using three-dimensional cell culture system.‏ ‎‡9 1‏
919		‎‡a roleofacidbaseimbalanceinstatininducedmyotoxicity‏ ‎‡A The role of acid-base imbalance in statin-induced myotoxicity‏ ‎‡9 1‏
919		‎‡a simultaneousquantificationofondansetronandtariquidarinratandhumanplasmausingahighperformanceliquidchromatographyultravioletmethod‏ ‎‡A Simultaneous quantification of ondansetron and tariquidar in rat and human plasma using a high performance liquid chromatography-ultraviolet method‏ ‎‡9 1‏
919		‎‡a simultaneousdeterminationofphenoxyethanolanditsmajormetabolitephenoxyaceticacidinratbiologicalmatricesbylcmsmswithpolarityswitchingapplicationtoadmestudies‏ ‎‡A Simultaneous determination of phenoxyethanol and its major metabolite, phenoxyacetic acid, in rat biological matrices by LC-MS/MS with polarity switching: Application to ADME studies‏ ‎‡9 1‏
919		‎‡a simpleandsensitivehplcuvmethodfordeterminationofbexaroteneinratplasma‏ ‎‡A Simple and sensitive HPLC-UV method for determination of bexarotene in rat plasma.‏ ‎‡9 1‏
919		‎‡a selfassemblingbenzothiazolebasedgelatorsamechanisticunderstandingofinvitrobioactivationandgelation‏ ‎‡A Self-Assembling Benzothiazole-Based Gelators: A Mechanistic Understanding of in Vitro Bioactivation and Gelation.‏ ‎‡9 1‏
919		‎‡a quantitativepredictionoforalbioavailabilityofalipophilicantineoplasticdrugbexaroteneadministeredinlipidicformulationusingacombinedinvitrolipolysismicrosomalmetabolismapproach‏ ‎‡A Quantitative Prediction of Oral Bioavailability of a Lipophilic Antineoplastic Drug Bexarotene Administered in Lipidic Formulation Using a Combined In Vitro Lipolysis/Microsomal Metabolism Approach‏ ‎‡9 1‏
919		‎‡a quantitativeanalysisoflabtolabvariabilityincaco2permeabilityassays‏ ‎‡A Quantitative analysis of lab-to-lab variability in Caco-2 permeability assays.‏ ‎‡9 1‏
919		‎‡a preventionofpaclitaxelinducedneuropathybyformulationapproach‏ ‎‡A Prevention of paclitaxel-induced neuropathy by formulation approach‏ ‎‡9 1‏
919		‎‡a physiologicallyrelevantinvitroinvivocorrelationivivcapproachforsildenafilwithsitedependentdissolution‏ ‎‡A Physiologically Relevant In Vitro-In Vivo Correlation (IVIVC) Approach for Sildenafil with Site-Dependent Dissolution‏ ‎‡9 1‏
919		‎‡a oraladministrationofcannabiswithlipidsleadstohighlevelsofcannabinoidsintheintestinallymphaticsystemandprominentimmunomodulation‏ ‎‡A Oral administration of cannabis with lipids leads to high levels of cannabinoids in the intestinal lymphatic system and prominent immunomodulation.‏ ‎‡9 1‏
919		‎‡a lipophilicactivatedesterprodrugapproachfordrugdeliverytotheintestinallymphaticsystem‏ ‎‡A Lipophilic activated ester prodrug approach for drug delivery to the intestinal lymphatic system‏ ‎‡9 1‏
919		‎‡a intradermalandtransdermaldrugdeliveryusingmicroneedlesfabricationperformanceevaluationandapplicationtolymphaticdelivery‏ ‎‡A Intradermal and transdermal drug delivery using microneedles - Fabrication, performance evaluation and application to lymphatic delivery‏ ‎‡9 1‏
919		‎‡a invitroanticancerpropertiesandbiologicalevaluationofnovelnaturalalkaloidjerantinineb‏ ‎‡A In vitro anticancer properties and biological evaluation of novel natural alkaloid jerantinine B.‏ ‎‡9 1‏
919		‎‡a hyperlipidaemiaaloneandincombinationwithacidosiscanincreasetheincidenceandseverityofstatininducedmyotoxicity‏ ‎‡A Hyperlipidaemia alone and in combination with acidosis can increase the incidence and severity of statin-induced myotoxicity‏ ‎‡9 1‏
919		‎‡a exposureassessmentofepidermalgrowthfactortovarioustissuesinmiceafterintravenousandsubcutaneousadministration‏ ‎‡A Exposure assessment of epidermal growth factor to various tissues in mice after intravenous and subcutaneous administration‏ ‎‡9 1‏
919		‎‡a dispositionoralbioavailabilityandtissuedistributionofzearalenoneinratsatvariousdoselevels‏ ‎‡A Disposition, oral bioavailability, and tissue distribution of zearalenone in rats at various dose levels.‏ ‎‡9 1‏
919		‎‡a dietaryfatsandpharmaceuticallipidexcipientsincreasesystemicexposuretoorallyadministeredcannabisandcannabisbasedmedicines‏ ‎‡A Dietary fats and pharmaceutical lipid excipients increase systemic exposure to orally administered cannabis and cannabis-based medicines‏ ‎‡9 1‏
919		‎‡a developmentofcordycepinformulationsforpreclinicalandclinicalstudies‏ ‎‡A Development of Cordycepin Formulations for Preclinical and Clinical Studies‏ ‎‡9 1‏
919		‎‡a developmentandvalidationofacosteffectiveandsensitivebioanalyticalhplcuvmethodfordeterminationoflopinavirinratandhumanplasma‏ ‎‡A Development and validation of a cost-effective and sensitive bioanalytical HPLC-UV method for determination of lopinavir in rat and human plasma‏ ‎‡9 1‏
919		‎‡a determinationofzearalenonebyliquidchromatographytandemmassspectrometryandapplicationtoapharmacokineticstudy‏ ‎‡A Determination of zearalenone by liquid chromatography/tandem mass spectrometry and application to a pharmacokinetic study.‏ ‎‡9 1‏
919		‎‡a cardiacglycosidecerberinexertsanticanceractivitythroughpi3kaktmtorsignaltransductioninhibition‏ ‎‡A Cardiac glycoside cerberin exerts anticancer activity through PI3K/AKT/mTOR signal transduction inhibition‏ ‎‡9 1‏
919		‎‡a assessmentofbisphenolaexposureinkoreanpregnantwomenbyphysiologicallybasedpharmacokineticmodeling‏ ‎‡A Assessment of bisphenol A exposure in Korean pregnant women by physiologically based pharmacokinetic modeling.‏ ‎‡9 1‏
996		‎‡2 DNB\|122070606X‏
996		‎‡2 ISNI\|0000000512358840‏
996		‎‡2 ISNI\|0000000464914135‏
996		‎‡2 ISNI\|0000000513541639‏
996		‎‡2 ISNI\|0000000473850284‏
996		‎‡2 ISNI\|0000000505547299‏
996		‎‡2 ISNI\|0000000377491859‏
996		‎‡2 ISNI\|0000000464888723‏
996		‎‡2 BNF\|12736844‏
996		‎‡2 ISNI\|0000000505750350‏
996		‎‡2 ISNI\|0000000464817212‏
996		‎‡2 ISNI\|0000000426077129‏
996		‎‡2 ISNI\|0000000473886789‏
996		‎‡2 ISNI\|0000000494089623‏
996		‎‡2 ISNI\|0000000040023654‏
996		‎‡2 ISNI\|0000000476967939‏
996		‎‡2 ISNI\|0000000474004346‏
996		‎‡2 ISNI\|0000000081530839‏
996		‎‡2 ISNI\|000000049416278X‏
996		‎‡2 LC\|n 84218241‏
996		‎‡2 ISNI\|000000050360689X‏
996		‎‡2 ISNI\|0000000473590144‏
996		‎‡2 LC\|no 94028189‏
996		‎‡2 ISNI\|0000000493004202‏
996		‎‡2 ISNI\|0000000464666581‏
996		‎‡2 ISNI\|0000000467781593‏
996		‎‡2 ISNI\|0000000047415423‏
996		‎‡2 RERO\|A003507271‏
996		‎‡2 RERO\|A003507272‏
996		‎‡2 ISNI\|0000000071469093‏
996		‎‡2 ISNI\|0000000459352246‏
996		‎‡2 DNB\|1156332605‏
996		‎‡2 ISNI\|0000000473797161‏
996		‎‡2 LC\|n 2018015698‏
996		‎‡2 ISNI\|0000000473783659‏
996		‎‡2 ISNI\|0000000512771205‏
996		‎‡2 ISNI\|0000000513802819‏
996		‎‡2 ISNI\|0000000465182976‏
996		‎‡2 ISNI\|0000000479286274‏
996		‎‡2 ISNI\|0000000480116053‏
996		‎‡2 ISNI\|0000000484956519‏
996		‎‡2 ISNI\|000000046097881X‏
996		‎‡2 ISNI\|0000000464605017‏
996		‎‡2 ISNI\|0000000476697051‏
996		‎‡2 DNB\|128501499‏
996		‎‡2 ISNI\|0000000397571071‏
996		‎‡2 ISNI\|0000000512522356‏
996		‎‡2 BIBSYS\|11018796‏
996		‎‡2 ISNI\|0000000473804261‏
996		‎‡2 LC\|no2010039255‏
996		‎‡2 ISNI\|0000000480116133‏
996		‎‡2 ISNI\|0000000477763321‏
996		‎‡2 SUDOC\|243280955‏
996		‎‡2 NII\|DA15019658‏
996		‎‡2 BIBSYS\|12007431‏
996		‎‡2 ISNI\|000000049406387X‏
996		‎‡2 ISNI\|000000046437460X‏
996		‎‡2 ISNI\|0000000493422041‏
996		‎‡2 CAOONL\|ncf10163644‏
996		‎‡2 ISNI\|0000000473875342‏
996		‎‡2 DNB\|1187983276‏
996		‎‡2 ISNI\|0000000508333800‏
996		‎‡2 SUDOC\|14033145X‏
996		‎‡2 ISNI\|0000000512744063‏
996		‎‡2 LC\|no2010165368‏
996		‎‡2 ISNI\|000000047927285X‏
996		‎‡2 ISNI\|000000049769321X‏
996		‎‡2 ISNI\|0000000467775580‏
996		‎‡2 ISNI\|0000000474078126‏
996		‎‡2 ISNI\|0000000477221194‏
996		‎‡2 DNB\|1154393011‏
996		‎‡2 ISNI\|0000000464815639‏
996		‎‡2 ISNI\|0000000467780275‏
996		‎‡2 ISNI\|0000000492251156‏
996		‎‡2 ISNI\|000000046467010X‏
996		‎‡2 ISNI\|0000000475915221‏
996		‎‡2 ISNI\|0000000512344748‏
996		‎‡2 ISNI\|0000000465118624‏
996		‎‡2 SUDOC\|133409120‏
996		‎‡2 ISNI\|0000000480270368‏
996		‎‡2 ISNI\|0000000512484265‏
996		‎‡2 ISNI\|0000000492319464‏
996		‎‡2 LC\|n 2024184187‏
996		‎‡2 ISNI\|0000000473812368‏
996		‎‡2 ISNI\|000000049405560X‏
996		‎‡2 ISNI\|0000000503691393‏
996		‎‡2 ISNI\|0000000505917210‏
996		‎‡2 ISNI\|0000000477770900‏
996		‎‡2 ISNI\|0000000512530444‏
996		‎‡2 ISNI\|0000000461115055‏
996		‎‡2 ISNI\|0000000463274009‏
996		‎‡2 ISNI\|0000000079063346‏
996		‎‡2 ISNI\|0000000468342787‏
996		‎‡2 BNF\|16125814‏
996		‎‡2 LC\|n 2007180318‏
996		‎‡2 ISNI\|0000000492038291‏
996		‎‡2 DNB\|171065603‏
996		‎‡2 ISNI\|0000000467641283‏
996		‎‡2 ISNI\|0000000467666747‏
996		‎‡2 ISNI\|0000000494061903‏
996		‎‡2 ISNI\|0000000468022986‏
996		‎‡2 BIBSYS\|90150658‏
996		‎‡2 ISNI\|0000000467822455‏
996		‎‡2 ISNI\|0000000493871509‏
996		‎‡2 LC\|n 2020180802‏
996		‎‡2 NTA\|37402166X‏
996		‎‡2 ISNI\|0000000492182162‏
996		‎‡2 ISNI\|000000047530165X‏
996		‎‡2 LC\|n 2001114266‏
996		‎‡2 ISNI\|0000000461106810‏
996		‎‡2 DNB\|13583080X‏
996		‎‡2 ISNI\|0000000476711466‏
996		‎‡2 SUDOC\|243288700‏
996		‎‡2 DNB\|127933816‏
996		‎‡2 DNB\|1158717652‏
996		‎‡2 ISNI\|0000000465033583‏
996		‎‡2 ISNI\|0000000464475259‏
996		‎‡2 ISNI\|0000000504796840‏
996		‎‡2 ISNI\|0000000050910011‏
996		‎‡2 ISNI\|0000000468167747‏
996		‎‡2 ISNI\|0000000474239022‏
996		‎‡2 ISNI\|0000000502761791‏
996		‎‡2 J9U\|987007413693805171‏
996		‎‡2 ISNI\|0000000492134259‏
996		‎‡2 NDL\|00991136‏
996		‎‡2 ISNI\|0000000512520852‏
996		‎‡2 ISNI\|0000000513307957‏
996		‎‡2 ISNI\|0000000468167982‏
996		‎‡2 NLA\|000035165079‏
996		‎‡2 ISNI\|000000046334330X‏
996		‎‡2 ISNI\|0000000477407220‏
996		‎‡2 DNB\|1030178151‏
996		‎‡2 ISNI\|0000000512256510‏
996		‎‡2 ISNI\|0000000464927315‏
996		‎‡2 ISNI\|0000000516852918‏
996		‎‡2 ISNI\|0000000465084524‏
996		‎‡2 ISNI\|000000047388162X‏
996		‎‡2 ISNI\|0000000054548064‏
996		‎‡2 BIBSYS\|90276147‏
996		‎‡2 ISNI\|0000000516883351‏
996		‎‡2 ISNI\|0000000467848102‏
996		‎‡2 J9U\|987007323253505171‏
996		‎‡2 LC\|nb2007010609‏
996		‎‡2 ISNI\|0000000459421870‏
996		‎‡2 ISNI\|0000000467671482‏
996		‎‡2 ISNI\|0000000473804077‏
996		‎‡2 NUKAT\|n 2016065299‏
996		‎‡2 NII\|DA07092095‏
996		‎‡2 ISNI\|000000049318678X‏
996		‎‡2 ISNI\|000000047387012X‏
996		‎‡2 ISNI\|0000000494060193‏
996		‎‡2 ISNI\|0000000505062961‏
996		‎‡2 ISNI\|0000000053061983‏
996		‎‡2 LC\|n 82079520‏
996		‎‡2 ISNI\|0000000479207484‏
996		‎‡2 LC\|no2019023554‏
996		‎‡2 BIBSYS\|9029721‏
996		‎‡2 ISNI\|0000000477408805‏
996		‎‡2 ISNI\|0000000464633659‏
996		‎‡2 ISNI\|0000000492405311‏
996		‎‡2 BIBSYS\|2063395‏
996		‎‡2 ISNI\|0000000473530379‏
996		‎‡2 ISNI\|000000049218941X‏
996		‎‡2 PLWABN\|9810705278205606‏
996		‎‡2 ISNI\|0000000516853080‏
996		‎‡2 LC\|no2013078397‏
996		‎‡2 ISNI\|0000000468325733‏
996		‎‡2 ISNI\|000000046508222X‏
996		‎‡2 ISNI\|0000000483379203‏
996		‎‡2 ISNI\|0000000463421320‏
996		‎‡2 J9U\|987007415718105171‏
996		‎‡2 ISNI\|0000000493271394‏
996		‎‡2 NDL\|001109589‏
996		‎‡2 ISNI\|0000000477778259‏
996		‎‡2 PLWABN\|9810558831005606‏
996		‎‡2 LC\|n 80094424‏
996		‎‡2 ISNI\|0000000493187213‏
996		‎‡2 ISNI\|0000000492026362‏
996		‎‡2 BIBSYS\|90623538‏
996		‎‡2 DNB\|13722091X‏
996		‎‡2 ISNI\|0000000463246315‏
996		‎‡2 ISNI\|0000000459887646‏
996		‎‡2 ISNI\|0000000138343672‏
996		‎‡2 BIBSYS\|7058374‏
996		‎‡2 ISNI\|0000000493186819‏
996		‎‡2 ISNI\|0000000503605168‏
996		‎‡2 J9U\|987007375967905171‏
996		‎‡2 ISNI\|0000000508334977‏
996		‎‡2 ISNI\|0000000468730464‏
996		‎‡2 ISNI\|0000000513221264‏
996		‎‡2 NII\|DA15419237‏
996		‎‡2 ISNI\|0000000063484517‏
996		‎‡2 ISNI\|000000050503440X‏
996		‎‡2 ISNI\|0000000465119678‏
996		‎‡2 ISNI\|0000000474790068‏
996		‎‡2 ISNI\|0000000509050642‏
996		‎‡2 ISNI\|0000000493140976‏
996		‎‡2 ISNI\|0000000513533479‏
996		‎‡2 ISNI\|0000000463437066‏
996		‎‡2 PLWABN\|9813295778305606‏
996		‎‡2 BNF\|14409600‏
996		‎‡2 ISNI\|0000000467641523‏
996		‎‡2 ISNI\|000000046446463X‏
996		‎‡2 LC\|n 90652293‏
996		‎‡2 ISNI\|0000000463408468‏
996		‎‡2 BIBSYS\|90233075‏
996		‎‡2 ISNI\|0000000494053700‏
996		‎‡2 DNB\|1057807141‏
996		‎‡2 ISNI\|000000048018315X‏
996		‎‡2 ISNI\|0000000083198462‏
996		‎‡2 ISNI\|0000000465126800‏
996		‎‡2 PLWABN\|9810597976005606‏
996		‎‡2 NII\|DA16162872‏
996		‎‡2 ISNI\|0000000474125172‏
996		‎‡2 ISNI\|0000000381706904‏
996		‎‡2 ISNI\|0000000492613954‏
996		‎‡2 ISNI\|0000000463367723‏
996		‎‡2 ISNI\|0000000468351018‏
996		‎‡2 LC\|n 2007182355‏
996		‎‡2 ISNI\|0000000474004100‏
996		‎‡2 ISNI\|0000000505331236‏
996		‎‡2 ISNI\|0000000479746920‏
996		‎‡2 ISNI\|0000000465106885‏
996		‎‡2 ISNI\|0000000039251115‏
996		‎‡2 RERO\|A003507219‏
996		‎‡2 DNB\|1049250095‏
996		‎‡2 ISNI\|0000000493239925‏
996		‎‡2 ISNI\|0000000491281644‏
996		‎‡2 ISNI\|0000000468167229‏
996		‎‡2 LC\|no2011159231‏
996		‎‡2 ISNI\|0000000505433195‏
996		‎‡2 ISNI\|0000000464386969‏
996		‎‡2 ISNI\|0000000468249734‏
996		‎‡2 ISNI\|0000000492076319‏
996		‎‡2 ISNI\|0000000511241747‏
996		‎‡2 ISNI\|0000000464374829‏
996		‎‡2 ISNI\|000000047396787X‏
996		‎‡2 ISNI\|0000000473915973‏
996		‎‡2 ISNI\|0000000463409305‏
996		‎‡2 ISNI\|0000000506837562‏
996		‎‡2 ISNI\|0000000464479487‏
996		‎‡2 BIBSYS\|98029465‏
996		‎‡2 ISNI\|000000049323397X‏
996		‎‡2 ISNI\|0000000467643027‏
996		‎‡2 ISNI\|0000000459421862‏
996		‎‡2 ISNI\|0000000474737697‏
996		‎‡2 ISNI\|0000000021976273‏
996		‎‡2 ISNI\|0000000461106351‏
996		‎‡2 LC\|no2018017003‏
996		‎‡2 ISNI\|0000000460872265‏
997		‎‡a 0 0 lived 0 0‏ ‎‡9 1‏

VIAF

Virtual International Authority File

Search